Showing results (71-80 of 83) with videos related to
Sort By:
Pageof 9
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 26, 2003
Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinomaG Cocconi, P Carlini, A Gamboni, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 19, 2004
Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancerS Di Cosimo, A Alimonti, G Ferretti, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 15, 2005
More information, more choice: an Italian database for oncology patientsA Bogliolo, W Russell-Edu, G Alloro, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 1, 2011
Retreatment with trastuzumab-based therapy after disease progression following lapatinib in HER2-positive metastatic breast cancerS Gori, F Montemurro, S Spazzapan, et al.Journal of Experimental & Clinical Cancer Research : CR|September 10, 2004
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedulesE Terzoli, C Nisticò, A Fabi, et al.Biomed Research International|May 31, 2014
Activity and safety of bevacizumab plus fotemustine for recurrent malignant gliomasV Vaccaro, A Fabi, A Vidiri, et al.Breast Cancer Research and Treatment|October 12, 1999
Breast cancer and timing of surgery during menstrual cycle: a 5-year analysis of 248 premenopausal womenM Milella, C Nisticò, V Ferraresi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
A re-evaluation of carcinoembryonic antigen (CEA) as a serum marker for breast cancer: a prospective longitudinal studyF Guadagni, P Ferroni, S Carlini, et al.British Journal of Cancer|June 1, 2006
Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trialsG Ferretti, E Bria, D Giannarelli, et al.Breast Cancer Research and Treatment|October 27, 2001
Serum tissue polypeptide specific antigen (TPS): a complementary tumor marker to CA 15-3 in the management of breast cancerR D'Alessandro, M Roselli, P Ferroni, et al.Pageof 9